OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	370
Prioritising health equity alongside donation safety – Authors' reply	297
Zanubrutinib-associated ecchymotic lesions	206
In the trenches	178
Correction to Lancet Haematol 2024; 11: e114–26	176
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	154
Correction to Lancet Haematol 2023; 10: e333–45	142
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	136
MRD-guided treatment cessation in multiple myeloma	125
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	123
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	120
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	118
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	109
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	94
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	94
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	94
Bedside art is good medicine	93
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	93
Artwork from trauma: the social life of medical data	85
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	80
Be compliant or compromise?	78
International Society on Thrombosis and Haemostasis Congress 2023	76
Blood cell defence against pathogens	74
Blood deserts: a vision to tackle blood inaccessibility	72
Rituximab versus active surveillance in patients with follicular lymphoma	71

Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	70
Correction to Lancet Haematol 2023; 10: e433–44	70
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	69
Production and supply of blood products in Brazil	66
Anaemia in a time of climate crisis	65
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	65
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	65
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	65
Extensively distributed erythema nodosum in VEXAS syndrome	63
USAID's enduring impact on anaemia management must be preserved	62
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	61
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	59
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	59
Sickle cell disease in India: current status and progress	58
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	56
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	56
Correction to Lancet Haematol 2025; 12: e294–303	56
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	55
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	55
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	55
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	54
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	53
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	52
Universal health coverage for children with cancer	52
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	51
Could improving mental health disorders help increase cancer survival?	51
Correction to Lancet Haematol 2022; 9: e200–07	50
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy	50
Correction to Lancet Haematol 2024; 11: e310–11	50
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	49
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	48
Oreofe Odejide—aiming to raise the bar in haematology care	48
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	47
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	47
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	47
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	47
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	46
Sickle cell disease—unity and patient-centred education	45
A long-awaited benchmark in lymphomatoid granulomatosis	45
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	45
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	44
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	44
Secondary haematological malignancies	40
Striking the right balance	40
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia	39
Lakshmi Nayak: striving to contain the brain's deadliest killers	38
Haemophilia—unparalleled progress but inadequate access	37
Reporting of trials with possible detrimental overall survival: a patient advocate perspective	37
2024 ASH Annual Meeting	36
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	36

Correction to Lancet Haematol 2024; 11: e521–29	36
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	36
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	34
Patients first: improving toxicity assessment and reporting	34
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	34
The challenge of defining the global burden of iron deficiency anaemia	33
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	33
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	33
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	33
Haematology and climate change	33
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospecti	32
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-lab	32
Should patients with haemophilia receive gene therapy?	32
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	31
Life beyond blood disorders	30
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	30
Removing unfair barriers to blood donation	29
In defence of individualised medicine	29
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	28
The Lancet Haematology at 10	28
Sovleplenib in immune thrombocytopenia	28
Thank you to The Lancet Haematology's peer reviewers in 2022	28
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	27
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	27
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	27
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group	27
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial	27
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care	26
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	26
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	26
Gene therapy in China: past, present, and future	25
A treatise on clinical trials	25
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	25
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	25
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	25
Breaking sex biases: access for all in haemophilia care	25
Acquired haemophilia in an Edo period Japanese surgical casebook	24
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	24
A rare blood disorder that created a watercolour storytelling movement	24
Melflufen in multiple myeloma: the conclusion matters	24
Needles were the least of my worries	24
Don Thomas: leading the charge to bone marrow transplantation	23
Clinical trial design change implementation for inclusive studies	23
Virtual twins for personalised CAR T-cell therapy in myeloma	23
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	23
Making a case for disease-modifying agents in myelofibrosis	23
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	23
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	23
Monumen-TAL progress in the treatment of relapsed multiple myeloma	22
Experience of the Anaemia Mukt Bharat anaemia control programme in India	22
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	22
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	22
Artificial intelligence in peripheral blood films: an evolving landscape	21
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	21
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	21
Reducing toxic waste: improving toxicity capture in childhood cancer	21
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	20
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	20
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	20
Lines of the haematology community	20
Mitapivat for treatment of pyruvate kinase deficiency	19
Making blood count	19
Sickle cell disease: a neglected health priority	18
Antifibrinolytics do not add to the benefits of platelet transfusion	18
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	18
Epistemic limitations of measurable residual disease in haematological malignancies	18
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	18
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	17
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	17
A comprehensive approach to therapy of haematological malignancies in older patients	17
Correction to Lancet Haematol 2025; 12: e562–63	17
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	17
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	17
The effects of revised haemoglobin cutoffs on the global burden of anaemia	17
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	16
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	16
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	16
Correction to Lancet Haematol 2021; 8: e55–66	15
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	15
Reactivating hope for TP53-mutated acute myeloid leukaemia?	15

Low-dose dasatinib: when less can be more	15
Correction to Lancet Haematol 2024; 11: e862–72	15
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	15
Lallindra Gooneratne—maintaining treatment flow amid crisis	15
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	15
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	14
Correction to Lancet Haematol 2023; 10: e203–12	14
An integrated approach to cardioprotection in lymphomas	14
Long term strategies for individuals with sickle cell disease	14
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	14
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	14
Sexually transmitted infections in the context of haematological malignancies	14
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	14
Time to define and refine maintenance strategies in acute myeloid leukaemia	14
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	14
Iron deficiency anaemia—an ongoing challenge	14
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	13
Oncology service priorities for the new UK Government	13
Follicular lymphoma: is more better or is less really more?	13
Virginia Abello Polo—a once-in-a-lifetime opportunity	13
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	13
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply	13
New hope, old challenges in myelodysplastic syndromes	13
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	13
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency	12
Correction to Lancet Haematol 2023; 10: e713–34	12
Isolated IgG4-related disease of the left maxillary antrum	12
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	12
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	12
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	12
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	11
Fitusiran prophylaxis in severe haemophilia without inhibitors	11
Correction to Lancet Haematol 2025; 12: e128–37	11
Concerns on perioperative anaemia management in the FIT trial	11
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	11
Mental health and psychological resilience in sickle cell disease	11
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice	11
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	10
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	10
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study	10
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	10
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	10
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	10
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	10
CAR T-cell therapies in China: rapid evolution and a bright future	10
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial	10
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	10
The dystopia of enforced childbirth	9
The role of conferences in tackling inequalities	9
A curious case of a neutrophilic horn	9
48th Annual Meeting of the EBMT	9
Correction to Lancet Haematol 2024; 11: e38–50	9
Correction to Lancet Haematol 2024; 11: e510–20	9